Posts Tagged ‘esclerosi múltiple’

Categories

Posted in:

Thursday October 26th, 2017

Computational Simulations Suggest Multiple Sclerosis is a Single Disease

IDIBAPS researchers publish a study in the journal Plos Computational Biology that supports the idea that multiple sclerosis (MS), which has widely varying symptoms and progression in different patients, is nonetheless a single disease with common underlying mechanisms. Pablo Villoslada, Head of the IDIBAPS group Pathogenesis and new treatments in Multiple Sclerosis, has coordinated the study. Ekaterina Kotelnikova, researcher at the same group, is the first author. Read the rest of this entry »

Comments Closed
Wednesday February 15th, 2017

IDIBAPS participates in an European project to enable personalized therapies in multiple sclerosis

A global partnership, coordinated by the Karolinska Institutet and in which IDIBAPS researchers participate, has received 15 million euros from the European Commission framework program Horizon2020 to find new and improved treatments for Multiple Sclerosis (MS). This project, named MultipleMS, involves universities and companies from 12 European countries and the USA, which will join efforts to adapt the development and application of therapies to each MS patient.

Read the rest of this entry »

Comments Closed

Categories

Posted in:

Wednesday January 04th, 2017

A new drug has been developed for the treatment of autoimmune diseases

IDIBAPS researchers have participated in a study that shows how a new experimental drug could curb a wide variety of autoimmune diseases such as asthma, psoriasis, Crohn’s disease or multiple sclerosis without blocking the body’s natural response against infections caused by pathogens.

Read the rest of this entry »

Comments Closed
Friday September 16th, 2016

IDIBAPS shares one milion euros to develop a project on Multiple Sclerosis

Neuroscientist Elena H. Martínez-Lapiscina, researcher of the IDIBAPS, shares with other XXXX experts a million euros that the Grant for Multiple Sclerosis Innovation (GMSI) award to the best translational research projects which contribute to increase or improve the knowledge on Multiple Sclerosis ( MS) and the development of new therapies. Dr. Elena H. Martínez-Lapiscina project, presented at the ECTRIMS congress (European Comitee for Treatment and Research in Multiple Sclerosis ), aims to give a boost to the understanding of the disease and the developement of therapies through the analysis of the retina of affected patients.

Read the rest of this entry »

Comments Closed

Categories

Posted in:

Tuesday May 24th, 2016

Diagnosis through the retina can predict the evolution of patients with Multiple Sclerosis

A study led by IDIBAPS researchers has shown the usefulness of optical coherence tomography (OCT), a diagnostic imaging technique widely used in ophthalmology, for monitoring patients with multiple sclerosis (MS). The analysis of the retina with this technique can determine the risk of clinical worsening of those patients. Dr. Pablo Villoslada, head of the IDIBAPS Pathogenesis and new treatments in Multiple Sclerosis, and Dr. Elena H. Martinez-Lapiscina, researcher of the same group and head of the Visual Pathway Lab, coordinate this article published in The Lancet Neurology. Researchers from centers in Spain, Italy, France, Germany, Czech Republic, Holland, Canada and the United States have been involved in this study.

Read the rest of this entry »

Comments Closed
Monday July 27th, 2015

Begins a clinical trial of a new technique to treat Multiple Sclerosis and Neuromyelitis Optica

The Spanish Agency for Medicines and Health Products (AEMPS) has approved a clinical trial in humans with an Antigen-Specific therapy with dendritic cells, a pioneering technique for the treatment of Multiple Sclerosis (MS) and Neuromyelitis Optica (NMO) in a more effective way and with fewer side effects. Dr. Pablo Villoslada, head of the IDIBAPS group Pathogenesis and new treatments in multiple sclerosis, and Dr. Daniel Benitez, researcher at the Inflammatory bowel disease IDIBAPS team, coordinate this trial led by the Hospital Clinic and driven by the Multiple Sclerosis Affected Group Foundation (GAEM) and “la Caixa” Foundation.

Read the rest of this entry »

Comments Closed
Page 1 of 212